Compare Moody's Corporation (MCO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Merck & Co., Inc. — how do they compare? Moody's Corporation trades at $488.84 (market cap $88.28B), while Merck & Co., Inc. trades at $125.69 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 3.5× Moody's Corporation's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MCO | MRK | |
|---|---|---|
Market Cap | $88.28B | $307.25B |
Sector | Financials | Health |
52-Week High | $539.61 | $129.52 |
52-Week Low | $412.23 | $77.60 |
Enterprise Value | $94.08B | $350.66B |
Dividend Yield | 0.82% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCO trades at $505.12, down 1.12% today, with a bullish technical signal from moving averages but overbought RSI readings near 76. The company shows strong fundamentals with Q1 2026 EPS beating estimates at $4.33, revenue growth to $7.72B in 2025, and robust profitability margins including a 31.69% net income margin. Recent news highlights AI integration initiatives and dividend sustainability, with a $1.03 dividend paid in June 2026.
Outlook remains positive given analyst consensus of $551.17 price target and 56% buy ratings, though valuation multiples like P/E of 36.65 pose risks if growth slows. Key risks include high debt levels and market sensitivity to credit cycles, but institutional support and recurring revenue model provide stability for long-term investors.
Merck (MRK) trades at $125.44, down 1.62% on the day, with a neutral technical signal. The company reported strong 2025 results with revenue of $65.01B and net income of $18.25B, though Q1 2026 saw a loss. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing positions. Valuation ratios include a P/E of 35.04 and ROE of 18.97%, indicating solid profitability but premium pricing.
Outlook remains positive with a consensus price target of $137.30, reflecting 9.5% upside potential. Risks include rising debt levels and competitive pressures in pharma. Analyst sentiment is bullish with 68% buy ratings, supporting a favorable investment case amid ongoing strategic acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
